Drug Type Small molecule drug |
Synonyms Magmesium Valproate, MagneVal |
Mechanism GABA transaminase inhibitors(Gamma-amino-N-butyrate transaminase inhibitors), GSK-3 inhibitors(Glycogen synthase kinase-3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date- |
Regulation- |
Molecular FormulaC16H32MgO4 |
InChIKeyAOKPYFGZNIEWKA-UHFFFAOYSA-N |
CAS Registry62959-43-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Epilepsy | CN | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Phase 2 | MX | 01 Sep 2007 |
Not Applicable | Second line | - | snwslvwwvx(ororkessdk) = supply, adherence and some drug interactions that in all cases they were responsible for therapeutic failure or adverse reactions to the initial medication tsyujmdbfl (wfjtxduuft ) View more | Positive | 24 Jun 2013 |